Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide - Amide derivatives of valproic acid

Epilepsy and Behavior

Volumn 46, Issue , 2015, Pages 72-78

  Mawasi, Hafiz ^a   Shekh Ahmad, Tawfeeq ^a   Finnell, Richard H ^b   Wlodarczyk, Bogdan J ^b   Bialer, Meir ^a,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

CNS drugs; Constitutional isomers; New antiepileptic drugs (AEDs); sec Butylpropylacetamide (SPD); Structure pharmacokinetic (PK) pharmacodynamic (PD) relationship; Valnoctamide (VCD)

Indexed keywords

ANTICONVULSIVE AGENT; CENTRAL DEPRESSANT AGENT; SEC BUTYLISOPROPYLACETAMIDE; SEC BUTYLPROPYLACETAMIDE; TERT BUTYLETHYLACETAMIDE; TERT BUTYLISOPROPYLACETAMIDE; UNCLASSIFIED DRUG; VALNOCTAMIDE; VALPROIC ACID; AMIDE; SEC-BUTYL-PROPYLACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; ELECTROSHOCK SEIZURE; EPILEPTIC STATE; FEMALE; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEURAL TUBE DEFECT; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; RAT; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; ISOMERISM; SEIZURES; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

AMIDES; ANIMALS; ANTICONVULSANTS; FEMALE; ISOMERISM; MALE; MICE; MICE, TRANSGENIC; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; VALPROIC ACID;

EID: 84937978253     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.02.040     Document Type: Article

References (34)

1. Barel S., Yagen B., Schurig V., Soback S., Pisani F., Perucca E., et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther 1997, 61:442-449.
2. Bialer M., Yagen B. Valproic acid - second generation. Neurotherapeutics 2007, 4:130-137.
3. Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012, 64:887-895.
4. Bialer M., Haj-Yehia A., Barzaghi N., Pisani F., Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol 1990, 38:289-291.
5. Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991, 20:114-122.
6. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 2010, 9:68-83.
7. White H.S., Alex A.B., Pollock A., Hen N., Shekh-Ahmad T., Wilcox K.S., et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012, 53:134-146.
8. Pouliot W., Bialer M., Hen N., Kaufmann D., Yagen B., Ricks K., et al. Electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013, 231:145-156.
9. Hen N., Shekh-Ahmad T., Yagen B., McDonough J.H., Finnell R.H., Wlodarczyk B., et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-propyl-butylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013, 56:6467-6477.
10. Bersudsky Y., Applebaum J., Gaiduk Y., Sharony L., Mishory A., Podberezsky A., et al. Valnoctamide as valproate substitute with low teratogenic potential in mania: double blind controlled clinical trial. Bipolar Disord 2010, (12):376-382.
11. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013, (103):2-30.
12. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the twelfth Eilat Conference (EILAT XII). Epilepsy Res 2015, (111):85-141.
13. Shekh-Ahmad T., Hen N., McDonough J.H., Yagen B., Bialer M. Valnoctamide and sec-propyl-butylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia 2013, 54:98-101.
14. Shekh-Ahmad T., Hen N., Yagen B., McDonough J.H., Finnell R.H., Wlodarczyk B.J., et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a new CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014, 55:353-361.
15. Kaufmann D., Yagen B., Minert A., Wlodarczyk B., Finnell R.H., Schurig V., et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 2010, 52:1228-1236.
16. Finnell R.H., Bielec B., Nau H. Anticonvulsant drugs: mechanisms and pathogenesis of teratogenicity. Handbook of experimental pharmacology 124 (drug toxicity in embryonic development II) 1997, 121-159. Springer-Verlag, Berlin.
17. Finnell R.H., Bennett G.D., Karras S.B., Mohl V.K. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 1988, 38:313-320.
18. Kaufmann D., Bialer M., Shimshoni J.A., Devor M., Yagen B. Synthesis and evaluation of the antiallodynic of novel amide and urea derivatives of valproic acid analogues. J Med Chem 2009, 52:7236-7248.
19. Finney D.J. Statistical logic in the monitoring of reactions to therapeutic drugs. Methods Inf Med 1971, 10:237-245.
20. Blotnik S., Bergman F., Bialer M. The disposition of valpromide, valproic acid and valnoctamide in brain, liver, plasma and urine of rats. Drug Metab Dispos 1996, 24:560-564.
21. Sobol E., Yagen Y., White H.S., Wilcox K.S., Lamb J.G., Pappo O., et al. Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonylurea, a novel second generation to valproic acid, antiepileptic drug. Neuropharmacology 2006, 51:933-946.
22. Pessah N., Bialer M., Wlodarczyk B., Finnell R.H., Yagen B. α-Fluoro-2,2,3,3-teteramethylcylcopropanecarboaxamide a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J Med Chem 2009, (52):2233-2242.
23. Spampanato J., Dudek E.F. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refectory status epilepticus. Epilepsia 2014, 55:e94-e98.
24. Haj-Yehia A., Bialer M. Structure-pharmacokinetic relationship in a series of valpromide isomers with antiepileptic activity. Pharm Res 1989, 6:683-689.
25. Haj-Yehia A., Bialer M. Structure pharmacokinetic relation in a series of short fatty acid amides that posses anticonvulsant activity. J Pharm Sci 1990, 79:719-724.
26. Spiegelman O., Yagen B., Levy R.H., Finnell R.H., Bennett G.D., Roeder M., et al. Strereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide - a CNS-active chiral amide derivative of valproic acid. Pharm Res 1999, 16:1582-1588.
27. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
28. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Sabers A., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, (10):609-6017.
29. European Medicines Agency (EMA) website:. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002186.jsp&mid=WC0b01ac058004d5c1.
30. Enna S.J., Willaims M. Challenged in the search for drugs to treat central nerve system disorders. J Pharmacol Exp Ther 2009, 329:404-411.
31. Swinney D.C., Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011, 10:507-519.
32. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in development. Epilepsy Res 2006, 69:272-284.
33. Smith M., Wilcox K.S., White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
34. Bialer M., Twyman R.E., White H.S. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 2004, 5:866-872.